Concord Biotech Limited vs Sun Pharmaceutical Industries Limited
Last updated: 25 October 2026
Concord Biotech vs Sun Pharma: A Financial Overview for Indian Investors
In the dynamic Indian pharmaceutical sector, Concord Biotech Limited and Sun Pharmaceutical Industries Limited represent two distinct players, both vying for investor attention. Concord Biotech, known for its focus on fermentation-based biopharmaceutical products, operates in a specialized niche. Sun Pharmaceutical Industries, on the other hand, is a global pharmaceutical giant with a vast portfolio spanning generics, branded generics, specialty products, and APIs. This comparison aims to provide Indian investors with a clear, data-driven perspective on these two companies, leveraging their latest available financial metrics to highlight their current standing and potential.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited (CONCORDBIO.NS) | Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) |
|---|---|---|
| Current Price | ₹1229.30 | ₹1748.00 |
| 52-Week High | ₹1579.40 | ₹2001.10 |
| 52-Week Low | ₹1014.80 | ₹1589.30 |
| 1-Year Return | -7.65% | -2.50% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Who Wins Where?
Valuation: Unfortunately, a direct comparison on traditional valuation metrics like Trailing P/E and Market Cap is not possible at this time, as these figures are not available for either company in the provided data. This absence limits our ability to assess whether one stock is relatively cheaper or more expensive than the other based on earnings or overall company size. Investors would need to seek out these crucial metrics for a comprehensive valuation analysis.
Returns: When it comes to 1-Year Returns, Sun Pharmaceutical Industries Limited clearly outperforms Concord Biotech Limited. Sun Pharma has seen a return of -2.50%, which, while negative, is significantly better than Concord Biotech's -7.65%. This indicates that Sun Pharma has demonstrated greater resilience or faced less headwinds over the past year compared to Concord Biotech. For investors prioritizing recent performance, Sun Pharma holds an edge.
Stability & Price Range: Analyzing the 52-Week High and Low offers insights into the price volatility and stability of each stock. Sun Pharma's 52-Week range (₹1589.30 to ₹2001.10) shows a higher absolute price point and a wider range in rupee terms compared to Concord Biotech (₹1014.80 to ₹1579.40). However, Sun Pharma's current price of ₹1748.00 is closer to its 52-Week Low than its High, suggesting it might be trading in the lower end of its recent range. Concord Biotech's current price of ₹1229.30 is also closer to its 52-Week Low, indicating both companies have seen a pull-back from their yearly highs. Sun Pharma, being a larger and more diversified entity, generally carries an perception of greater stability, though this data alone doesn't directly confirm it without market cap or volatility metrics.
MoneyDock Verdict
Aggressive Investor: With limited valuation data, an aggressive investor might lean towards Sun Pharma given its comparatively better 1-year return, suggesting stronger market sentiment or operational performance in the short term. However, the lack of P/E and Market Cap data makes it difficult to assess true 'aggressive' potential based on undervaluation or growth prospects without further research.
Conservative Investor: For a conservative investor, the absence of key metrics like Trailing P/E and Market Cap for both companies presents a significant hurdle. Without these foundational data points, making a fully informed, conservative decision is challenging. Sun Pharma, as a larger, more established player, might inherently carry less perceived risk due to its scale and diversification, but this cannot be confirmed solely from the provided numbers. More data is needed for a truly conservative approach.
Long-term SIP Investor: A long-term SIP investor typically looks for consistent growth and strong fundamentals. While Sun Pharma has shown a less negative 1-year return, the absence of crucial long-term growth indicators (like historical P/E trends, market share, or consistent profitability) makes a definitive recommendation difficult. Both stocks have seen their prices decline over the last year. A SIP investor would need to delve deeper into each company's long-term strategy, market positioning, and financial health beyond these immediate figures to make an educated choice.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.